EU's CHMP negative on Antigenics' therapeutic cancer vaccine Oncophage
This article was originally published in Scrip
The EU's CHMP has turned down what could have been the first therapeutic cancer vaccine approved in the EU, Antigenics' novel therapy Oncophage (HSPPC-96; vitespen), as an adjuvant treatment for renal cell carcinoma (RCC). The agency said that Oncophage did not demonstrate its effectiveness in prolonging the length of time kidney cancer patients lived without their cancer recurring.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.